Un-Audited Financial Results For The Quarter Ended On 31St December, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.1 pts more than Nifty Microcap 250 and 1.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Zenith Healthcare reported unaudited results for the quarter ended 31 Dec 2025. Revenue from operations rose to ₹248.30 lakhs, up about 7.7% from ₹230.52 lakhs in Q3 of the previous year. Net profit for the quarter came in at ₹22.41 lakhs (EPS ₹0.042), compared to a loss of ₹29.22 lakhs in the same quarter last year, marking a clear YoY turnaround. For the nine-month period, revenue was nearly flat at ₹790.07 lakhs versus ₹790.44 lakhs, but net profit swung to a surplus of ₹34.71 lakhs from a loss of ₹4.27 lakhs. The improvement was driven mainly by a sharp drop in cost of materials and broadly stable operating expenses. Statutory auditors Doshi Doshi & Co issued an unmodified limited review report with no qualifications.
The sharp swing back to profit is a positive signal on operational health, but the absolute earnings remain tiny and nine-month revenue is flat, so this is a modest positive rather than a strong re-rating catalyst. Shareholders should watch whether the profit recovery sustains with revenue growth in coming quarters.